Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTS NASDAQ:HSDT NASDAQ:PSTV NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$0.91-1.1%$0.59$0.38▼$3.03$144.31M2.112.51 million shs1.88 million shsHSDTSolana$2.29-3.0%$2.07$1.59▼$217.63$133.71M1.06225,629 shs107,037 shsPSTVPlus Therapeutics$6.59-4.4%$5.72$2.90▼$23.42$45.36M1.4156,668 shs128,165 shsRCELAvita Medical$4.58+2.2%$4.34$3.22▼$7.12$140.96M1.9258,193 shs183,847 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health0.00%+5.69%+56.56%+94.23%-50.57%HSDTSolana0.00%-0.43%+11.17%+12.81%-98.95%PSTVPlus Therapeutics0.00%+25.52%-9.48%-4.15%-22.29%RCELAvita Medical0.00%+0.44%+5.77%-4.38%-29.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$0.91-1.1%$0.59$0.38▼$3.03$144.31M2.112.51 million shs1.88 million shsHSDTSolana$2.29-3.0%$2.07$1.59▼$217.63$133.71M1.06225,629 shs107,037 shsPSTVPlus Therapeutics$6.59-4.4%$5.72$2.90▼$23.42$45.36M1.4156,668 shs128,165 shsRCELAvita Medical$4.58+2.2%$4.34$3.22▼$7.12$140.96M1.9258,193 shs183,847 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health0.00%+5.69%+56.56%+94.23%-50.57%HSDTSolana0.00%-0.43%+11.17%+12.81%-98.95%PSTVPlus Therapeutics0.00%+25.52%-9.48%-4.15%-22.29%RCELAvita Medical0.00%+0.44%+5.77%-4.38%-29.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 2.40Hold$5.40493.67% UpsideHSDTSolana 2.50Moderate Buy$3.5052.84% UpsidePSTVPlus Therapeutics 2.43Hold$58.00780.12% UpsideRCELAvita Medical 2.33Hold$7.2558.30% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, RCEL, GUTS, and HSDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026RCELAvita Medical Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$3.50 ➝ $6.005/12/2026GUTSFractyl Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/27/2026HSDTSolana Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/24/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/23/2026HSDTSolana B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.004/22/2026HSDTSolana B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026HSDTSolana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.004/8/2026RCELAvita Medical D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/6/2026HSDTSolana Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold ➝ Buy$4.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$90K1,603.42N/AN/A$0.13 per share7.00HSDTSolana$6.02M22.21N/AN/A$3.39 per share0.68PSTVPlus Therapeutics$5.21M8.70N/AN/A$1.74 per share3.79RCELAvita Medical$71.61M1.97N/AN/A($0.75) per share-6.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$140.95M-$1.29N/AN/AN/AN/A-4,053.15%-96.41%8/11/2026 (Estimated)HSDTSolana-$40.89M-$109.67N/AN/AN/A-1,427.15%-67.57%-24.09%N/APSTVPlus Therapeutics-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%5/29/2026 (Estimated)RCELAvita Medical-$48.59M-$1.57N/AN/AN/A-62.67%N/A-78.92%8/6/2026 (Estimated)Latest PSTV, RCEL, GUTS, and HSDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026PSTVPlus Therapeutics-$0.8480N/AN/AN/A$0.97 millionN/A5/15/2026Q1 2026HSDTSolana-$0.34-$1.30-$0.96-$1.30$3.40 million$3.62 million5/15/2026Q1 2026PSTVPlus Therapeutics-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million5/14/2026Q1 2026RCELAvita Medical-$0.35-$0.35N/A-$7.00$18.30 million$19.25 million5/12/2026Q1 2026GUTSFractyl Health-$0.17$0.06+$0.23$0.06N/AN/A3/31/2026Q4 2025HSDTSolana-$26.50$4.25+$30.75$4.25$0.14 million$5.23 million3/24/2026Q4 2025GUTSFractyl Health-$0.19$0.15+$0.34-$0.07N/AN/A3/12/2026Q4 2025PSTVPlus Therapeutics-$0.03$6.25+$6.28N/A$1.23 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/AHSDTSolanaN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health1.414.284.28HSDTSolanaN/A9.909.96PSTVPlus TherapeuticsN/A2.271.23RCELAvita MedicalN/A0.470.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/AHSDTSolana18.63%PSTVPlus Therapeutics3.28%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipGUTSFractyl Health8.52%HSDTSolana14.40%PSTVPlus Therapeutics2.50%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health102158.65 million145.13 millionN/AHSDTSolana3058.39 million49.98 millionNot OptionablePSTVPlus Therapeutics206.88 million6.71 millionNot OptionableRCELAvita Medical13030.78 million29.92 millionOptionablePSTV, RCEL, GUTS, and HSDT HeadlinesRecent News About These CompaniesAvita Medical (NASDAQ:RCEL) Lowered to "Sell" Rating by Wall Street ZenMay 24 at 1:06 AM | americanbankingnews.comAVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth TranscriptMay 22 at 1:09 AM | seekingalpha.comAVITA Medical to Host Investor Webinar BriefingMay 17, 2026 | globenewswire.comBTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)May 17, 2026 | theglobeandmail.comLake Street upgrades AVITA Medical (RCEL)May 16, 2026 | msn.comAvita Medical (NASDAQ:RCEL) Stock Rating Upgraded by Wall Street ZenMay 16, 2026 | americanbankingnews.comAvita (RCEL) Q1 2026 Earnings Call TranscriptMay 15, 2026 | theglobeandmail.comAvita Medical Q1 Earnings Call HighlightsMay 14, 2026 | marketbeat.comAVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comAVITA Medical Reports First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comAvita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by BrokeragesMay 11, 2026 | marketbeat.comAvita Medical (RCEL) Expected to Announce Earnings on ThursdayMay 7, 2026 | marketbeat.comAvita Medical (NASDAQ:RCEL) Stock Rating Lowered by Wall Street ZenMay 2, 2026 | marketbeat.comAVITA Medical Names Cary Vance as Chief Executive OfficerApril 30, 2026 | globenewswire.comAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GOApril 29, 2026 | globenewswire.comAVITA Medical to Announce First Quarter 2026 Financial ResultsApril 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCELApril 21, 2026 | globenewswire.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call TranscriptApril 16, 2026 | seekingalpha.comAVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationApril 15, 2026 | globenewswire.comAvita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?April 15, 2026 | zacks.comAVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin GraftingApril 14, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026UPS Stock Reversal Is Backed by Institutions—And a 6% YieldBy Thomas Hughes | April 29, 2026Amazon Weaponizes Logistics, Triggering Sector-Wide SelloffBy Jeffrey Neal Johnson | May 5, 2026PSTV, RCEL, GUTS, and HSDT Company DescriptionsFractyl Health NASDAQ:GUTS$0.91 -0.01 (-1.13%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.91 0.00 (-0.18%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Solana NASDAQ:HSDT$2.29 -0.07 (-2.97%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.28 -0.01 (-0.44%) As of 05/22/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.Plus Therapeutics NASDAQ:PSTV$6.59 -0.30 (-4.35%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.64 +0.05 (+0.83%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Avita Medical NASDAQ:RCEL$4.58 +0.10 (+2.23%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.65 +0.07 (+1.48%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
